News & Events

Results of Operations and Financial Condition. On April 28, 2026 , Incyte Corporation issued a press release announcing financial results for its first fiscal quarter ended March 31, 2026. The full text of the press release is furnished as Exhibit 99.1.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 26, 2026, Susanne Schaffert notified Incyte Corporation (the “Company”) that she was resigning from the Company’s Board of Directors (the “Board”), effective as of April 15, 2026. The resignation of Dr. Schaffert, who has been a member of the Company’s Board since 2022, was not the result of any disagreement with the Company on any matter…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 25, 2026, Incyte Corporation (the “Company”) announced title changes for certain current members of its executive leadership team, effective immediately. Pablo J. Cagnoni’s title was changed to President, Incyte and Global Head of Research and Development; Steven H. Stein’s title was changed to Executive Vice President, Chief Medical Offic…

Other Events. On February 27, 2026, the U.S. Food and Drug Administration (“FDA”) issued a Complete Response Letter (“CRL”) for the supplemental Biologics License Application (“sBLA”) for Zynyz® (retifanlimab-dlwr) injection (375mg) for an additional indication for the treatment of adult patients with metastatic non-small cell lung cancer (“NSCLC”) in combination with platinum-based chemotherapy. The sBLA was supported by positive efficacy and safety data from the Phase 3 POD1UM-304 trial ann…

Results of Operations and Financial Condition. On February 10, 2026, Incyte Corporation issued a press release announcing financial results for its fourth fiscal quarter and year ended December 31, 2025. The full text of the press release is furnished as Exhibit 99.1.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Director Retirement On December 10, 2025, Hervé Hoppenot notified Incyte Corporation (the “Company”) that he was retiring from the Company’s Board of Directors, effective immediately. Mr. Hoppenot, the former Chairman and Chief Executive Officer of the Company, has been a member of the Company’s Board of Directors since 2014. 2 SIGNATURE Pursuant t…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 30, 2025, the Board of Directors of Incyte Corporation (the “Company”) appointed Thomas Tray, the Company’s current Vice President, Finance and Chief Accounting Officer (principal accounting officer), to the additional position of principal financial officer, effective as of September 16, 2025. Mr. Tray, age 48, joined the Company in J…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 4, 2025, Christiana Stamoulis, Executive Vice President and Chief Financial Officer of Incyte Corporation (the “Company”), notified the Company of her intent to step down from her role to pursue another opportunity, effective September 16, 2025. Ms. Stamoulis will remain at the Company until then to support a smooth transition. The Compan…

Other Events On May 11, 2025, Incyte Corporation (the “Company”) and Novartis Pharma AG (“Novartis”) entered into a settlement agreement (the “Settlement Agreement”) with respect to litigation initiated by Novartis and relating to the duration of royalty payments owed by the Company to Novartis under the Collaboration and License Agreement dated November 24, 2009, as amended, between the Company and Novartis. As of March 31, 2025, the Company had approximately $537.1 million of accrued royalt…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 6, 2025, Barry P. Flannelly, Executive Vice President, General Manager, North America of Incyte Corporation (the “Company”), announced his retirement from the Company and stepped down from that role on that date, effective with the commencement of employment of his successor. Dr. Flannelly will remain employed by the Company through July…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information contained in

Entry Into a Material Definitive Agreement . On June 28, 2024, Incyte Corporation (the “Company”) and its subsidiary, Incyte Holdings Corporation (“Incyte Holdings”), entered into Amendment No. 2 (“Amendment No. 2”) to the Revolving Credit and Guaranty Agreement dated as of August 21, 2021 among the Company, as borrower, Incyte Holdings, as a guarantor, the lenders from time to time party thereto, J.P. Morgan Chase Bank, N.A. as administrative agent, and the other financial institutions party…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers . On September 8, 2023, Maria E. Pasquale, Executive Vice President, General Counsel and Corporate Secretary of Incyte Corporation (the “Company”), notified the Company of her intention to retire effective November 1, 2023. Ms. Pasquale’s roles as Executive Vice President, General Counsel and Corporate Secretary of the Company may end earlier than h…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers . Election of Directors Effective October 1, 2022, the Board of Directors of Incyte Corporation (the “Company”) increased the number of authorized members of the Board of Directors of the Company to nine and elected Susanne Schaffert, Ph.D., a member of the Board of Directors of the Company. Dr. Schaffert, age 55, previously spent 26 years at the ph…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Director Retirement On April 18, 2022, Wendy L. Dixon notified Incyte Corporation (the “Company”) that she will be retiring from the Company’s Board of Directors, effective at the time of the Company’s 2022 Annual Meeting of Stockholders. Dr. Dixon has been a member of the Company’s Board of Directors since 2010. 2 SIGNATURE Pursuant to the require…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 10, 2022, Paul Trower notified Incyte Corporation (the “Company”) of his intention to retire as Division Vice President, Finance and Principal Accounting Officer of the Company effective March 11, 2022. Effective March 11, 2022, the board of directors of the Company appointed Thomas Tray, age 44, as the Company’s Vice President, Finance…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers . Election of Directors Effective September 27, 2021, the Board of Directors of Incyte Corporation (the “Company”) increased the number of authorized members of the Board of Directors of the Company to nine and elected Otis W. Brawley, M.D., a member of the Board of Directors of the Company. Dr. Brawley, age 62, has served as a Bloomberg Distinguish…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information contained in

Entry Into a Material Definitive Agreement. On August 18, 2021, Incyte Corporation (the “Company”) and its subsidiary, Incyte Holdings Corporation (“Incyte Holdings”), entered into a revolving credit and guaranty agreement (the “Credit Agreement”) among the Company, as borrower, Incyte Holdings, as a guarantor, the lenders from time to time party thereto (the “Lenders”), J.P. Morgan Chase Bank, N.A. as administrative agent, and the other financial institutions party thereto. Under the Credit…